The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Open accessAbstract
Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., & Iruela-Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,046
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615
LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis
Boucher, P., Gotthardt, M., Li, W.-P., Anderson, R. G. W., & Herz, J. (2003) · Science · doi:10.1126/science.1082095 · Cited by 581
Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000765 · Cited by 574
The Role of Endoplasmic Reticulum Stress in the Progression of Atherosclerosis
Tabas, I. (2010) · Circulation Research · doi:10.1161/circresaha.110.224766 · Cited by 480
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Farmakis, D., Parissis, J., & Filippatos, G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.026 · Cited by 387
Giordano, F. J., Gerber, H.-P., Williams, S.-P., VanBruggen, N., Bunting, S., Ruiz-Lozano, P., Gu, Y., Nath, A. K., Huang, Y., Hickey, R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091415198 · Cited by 370
Management of hypertension in angiogenesis inhibitor-treated patients
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 347
The Relationship Between Pre-Eclampsia and Peripartum Cardiomyopathy
Bello, N., Rendon, I. S. H., & Arany, Z. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.717 · Cited by 336
Oka, M., Homma, N., Taraseviciene-Stewart, L., Morris, K. G., Kraskauskas, D., Burns, N., Voelkel, N. F., & McMurtry, I. F. (2007) · Circulation Research · doi:10.1161/01.res.0000261658.12024.18 · Cited by 331
Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen, D. L. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.005 · Cited by 329
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2561 · Cited by 305
Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer
VOGELZANG, N. J., BOSL, G. J., JOHNSON, K., & KENNEDY, B. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-3-288 · Cited by 296
Aichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
Yoon, Y.-S., Uchida, S., Masuo, O., Cejna, M., Park, J.-S., Gwon, H.-C., Kirchmair, R., Bahlman, F., Walter, D., Curry, C., et al. (2005) · Circulation · doi:10.1161/01.cir.0000162472.52990.36 · Cited by 288
Lemmens, K., Doggen, K., & De Keulenaer, G. W. (2007) · Circulation · doi:10.1161/circulationaha.107.690487 · Cited by 286
Kappers, M. H. W., van Esch, J. H. M., Sluiter, W., Sleijfer, S., Danser, A. H. J., & van den Meiracker, A. H. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149690 · Cited by 284
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Ranpura, V., Hapani, S., Chuang, J., & Wu, S. (2010) · Acta Oncologica · doi:10.3109/02841860903524396 · Cited by 276
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
Polk, A., Vistisen, K., Vaage-Nilsen, M., & Nielsen, D. L. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-47 · Cited by 267
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Jensen, S. A., & Sørensen, J. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0178-1 · Cited by 232
DOLL, D. C., LIST, A. F., GRECO, F. A., HAINSWORTH, J. D., HANDE, K. R., & JOHNSON, D. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-48 · Cited by 225
Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer
Gietema, J., Meinardi, M., Messerschmidt, J., Gelevert, T., Alt, F., Uges, D., & Th Sleijfer, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02044-4 · Cited by 216
Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity
Chintalgattu, V., Rees, M. L., Culver, J. C., Goel, A., Jiffar, T., Zhang, J., Dunner, K., Pati, S., Bankson, J. A., Pasqualini, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005066 · Cited by 214
Hamnvik, O. R., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M., Kaymakcalan, M. D., & Williams, J. S. (2015) · Cancer · doi:10.1002/cncr.28972 · Cited by 203
De Keulenaer, G. W., Doggen, K., & Lemmens, K. (2010) · Circulation Research · doi:10.1161/circresaha.109.205906 · Cited by 201
Iliescu, C. A., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K. P., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26379 · Cited by 190
Self-citationChintalgattu, V., Ai, D., Langley, R. R., Zhang, J., Bankson, J. A., Shih, T. L., Reddy, A. K., Coombes, K. R., Daher, I. N., Pati, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39434 · Cited by 188
Iliescu, C., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26375 · Cited by 186
Self-citationLung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series
Bergeron, A., Réa, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A., & Rousselot, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-715cr · Cited by 184
Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib
Aman, J., van Bezu, J., Damanafshan, A., Huveneers, S., Eringa, E. C., Vogel, S. M., Groeneveld, A. B. J., Vonk Noordegraaf, A., van Hinsbergh, V. W. M., & van Nieuw Amerongen, G. P. (2012) · Circulation · doi:10.1161/circulationaha.112.134304 · Cited by 177
Endothelium-Derived Neuregulin Protects the Heart Against Ischemic Injury
Hedhli, N., Huang, Q., Kalinowski, A., Palmeri, M., Hu, X., Russell, R. R., & Russell, K. S. (2011) · Circulation · doi:10.1161/circulationaha.110.991125 · Cited by 173
Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages
Michel, J.-B., Martin-Ventura, J. L., Nicoletti, A., & Ho-Tin-Noé, B. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.020 · Cited by 172
5-Fluorouracil induces arterial vasocontractions
Südhoff, T., Enderle, M.-D., Pahlke, M., Petz, C., Teschendorf, C., Graeven, U., & Schmiegel, W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh150 · Cited by 168
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
Meyer, T. V., Robles-Carrillo, L. D., Robson, T., Länger, F. P., DESAI, H., Davila, M., Amaya, M., Francis, J. L., & Amirkhosravi, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03212.x · Cited by 160
Reinert, T., Baldotto, C. S. D. R., Nunes, F. A. P., & Scheliga, A. A. D. S. (2013) · Journal of Cancer Research · doi:10.1155/2013/480608 · Cited by 160
Hemnes, A. R., Zaiman, A., & Champion, H. C. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00245.2007 · Cited by 157
Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & Keulenaer, G. W. D. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv132 · Cited by 156
Imatinib Attenuates Diabetes-Associated Atherosclerosis
Lassila, M., Allen, T. J., Cao, Z., Thallas, V., Jandeleit-Dahm, K. A. M., Candido, R., & Cooper, M. E. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000124105.39900.db · Cited by 142
Kappers, M. H. W., Smedts, F. M. M., Horn, T., van Esch, J. H. M., Sleijfer, S., Leijten, F. P. J., Wesseling, S., Strevens, H., Danser, A. H. J., & van den Meiracker, A. H. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173559 · Cited by 140
Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina
Stewart, T. V., Pavlakis, N., & Ward, M. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02144.x · Cited by 132
Small, H. Y., Montezano, A. C. I., Rios, F. J. O., Savoia, C., & Touyz, R. M. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.011 · Cited by 131
May, D., Gilon, D., Djonov, V., Itin, A., Lazarus, A., Gordon, O. M., Rosenberger, C., & Keshet, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707778105 · Cited by 126
Kappers, M. H. W., de Beer, V. J., Zhou, Z., Danser, A. H. J., Sleijfer, S., Duncker, D. J., van den Meiracker, A. H., & Merkus, D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.182220 · Cited by 124
Immune-Mediated Complications during Interferon Therapy in Hematological Patients
Raanani, P., & Ben‐Bassat, I. (2002) · Acta Haematologica · doi:10.1159/000057631 · Cited by 123
Defective Angiogenesis Delays Thrombus Resolution
Alias, S., Redwan, B., Panzenboeck, A., Winter, M., Schubert, U., Voswinckel, R., Frey, M. K., Jakowitsch, J., Alimohammadi, A., Hobohm, L., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302991 · Cited by 123
Tomita, Y., Uemura, H., Fujimoto, H., Kanayama, H., Shinohara, N., Nakazawa, H., Imai, K., Umeyama, Y., Ozono, S., Naito, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.014 · Cited by 122
Steingart, R. M., Bakris, G. L., Chen, H. X., Chen, M., Force, T. L., Ivy, S. P., Leier, C. V., Liu, G., Lenihan, D. J., Lindenfeld, J. M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.10.018 · Cited by 116
Qi, W., He, A., Shen, Z., & Yao, Y. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12149 · Cited by 114
Baliga, R. S., Milsom, A. B., Ghosh, S. M., Trinder, S. L., MacAllister, R. J., Ahluwalia, A., & Hobbs, A. J. (2012) · Circulation · doi:10.1161/circulationaha.112.100586 · Cited by 110
Clinical cardiac safety profile of nilotinib
Kim, T. D., le Coutre, P., Schwarz, M., Grille, P., Levitin, M., Fateh‐Moghadam, S., Giles, F. J., Dörken, B., Haverkamp, W., & Köhncke, C. (2012) · Haematologica · doi:10.3324/haematol.2011.058776 · Cited by 109
Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis
Herrmann, J., Saguner, A. M., Versari, D., Peterson, T. E., Chade, A., Olson, M. L., Lerman, L. O., & Lerman, A. (2007) · Circulation Research · doi:10.1161/circresaha.107.152959 · Cited by 109
Self-citationWinnik, S. H., Lohmann, C., Siciliani, G., von Lukowicz, T., Kuschnerus, K., Kränkel, N., Brokopp, C. E., Enseleit, F., Michels, S., Ruschitzka, F. T., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.03.010 · Cited by 103
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Qi, W., Lin, F., Sun, Y., Tang, L., He, A., Yao, Y., & Shen, Z. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2025-5 · Cited by 90
Jay, S. M., Murthy, A. C., Hawkins, J. F., Wortzel, J. R., Steinhauser, M. L., Alvarez, L. M., Gannon, J., MacRae, C. A., Griffith, L. G., & Lee, R. T. (2013) · Circulation · doi:10.1161/circulationaha.113.002203 · Cited by 89
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy
Fraum, T. J., Kreisl, T. N., Sul, J., Fine, H. A., & IWAMOTO, F. M. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0579-4 · Cited by 89
Tefferi, A., & Letendre, L. (2011) · American Journal of Hematology · doi:10.1002/ajh.22051 · Cited by 86
Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis
Bello, N. A., & Arany, Z. P. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.01.004 · Cited by 85
Qi, W., Shen, Z., Tang, L., & Yao, Y. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.04.004 · Cited by 84
Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature
Grunwald, M. R., Howie, L. J., & Diaz, L. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5278 · Cited by 81
van der Veldt, A. A. M., de Boer, M. P., Boven, E., Eringa, E. C., van den Eertwegh, A. J. M., van Hinsbergh, V. W. M., Smulders, Y. M., & Serné, E. H. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283359c79 · Cited by 76
Levato, L., Cantaffa, R., Kropp, M. G., Magro, D., Piro, E., & Molica, S. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12096 · Cited by 75
Vascular Events Associated with Alpha Interferon Therapy
Alzahrani, H. A., Gupta, V. K., Minden, M. D., Messner, H. A., & Lipton, J. H. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000055066 · Cited by 74
Bei, Y., Hua-Huy, T., Duong‐Quy, S., Nguyen, V.-H., Chen, W., Nicco, C., Batteux, F., & Dinh‐Xuan, A. T. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.07.008 · Cited by 73
Khasraw, M., Holodny, A. I., Goldlust, S. A., & DeAngelis, L. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr148 · Cited by 73
Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis
Herrmann, J., Soares, S. M., Lerman, L. O., & Lerman, A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.047 · Cited by 65
Self-citationChislock, E. M., Ring, C., & Pendergast, A. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304188110 · Cited by 65
Breccia, M., Muscaritoli, M., Gentilini, F., Latagliata, R., Carmosino, I., Fanelli, F. R., & Alimena, G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.01.024 · Cited by 65
van Heeckeren, W. J., Bhakta, S., Ortiz, J., Duerk, J. L., Cooney, M. M., Dowlati, A., McCrae, K. R., & Remick, S. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8801 · Cited by 63
Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
Franco, T. A. E. R. A. E. S. H. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3960 · Cited by 62
Herrmann, J., & Lerman, A. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.07.003 · Cited by 61
Self-citationGeisberg, C. A., Wang, G., Safa, R., Smith, H., Anderson, B., Peng, X., Veerkamp, B., Zhao, D. X.-M., Blakemore, D. L., Yu, C., et al. (2011) · Coronary Artery Disease · doi:10.1097/mca.0b013e32834d3346 · Cited by 57
Atkinson, B. J., Cauley, D. H., Ng, C. S., Millikan, R. E., Xiao, L., Corn, P. G., Jonasch, E. W., & Tannir, N. M. (2013) · British Journal of Urology · doi:10.1111/bju.12420 · Cited by 53
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer
Cunningham, D., Powles, T. J., Dowsett, M., Hutchison, G., Brodie, A. M. H., Ford, H. T., Gazet, J.-C., & Coombes, R. C. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00570496 · Cited by 52
Périard, D., Boulanger, C. M., Eyer, S., Amabile, N., Pugin, P., Gerschheimer, C., & Hayoz, D. (2007) · Stroke · doi:10.1161/strokeaha.106.479733 · Cited by 51
Pantaleo, M. A., Mandrioli, A., Saponara, M., Nannini, M., Erente, G., Lolli, C., & Biasco, G. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-231 · Cited by 49
Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy
Gui, C., Zhu, L., Hu, M. C., Lei, L., & Long, Q. (2012) · Cardiovascular Pathology · doi:10.1016/j.carpath.2011.12.006 · Cited by 47
Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy
Schwarzer, S., Eber, B., Greinix, H., et al. (1991) · European Heart Journal · doi:10.1093/eurheartj/12.6.748 · Cited by 46
Schroll, S., Arzt, M. E., Sebah, D., Nüchterlein, M., Blumberg, F. C., & Pfeifer, M. A. (2009) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2009.11.005 · Cited by 45
Grasemann, H., Dhaliwal, R., Ivanovska, J., Kantores, C., McNamara, P. J., Scott, J. A., Belik, J., & Jankov, R. P. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00328.2014 · Cited by 44
Lee, A. H., Dhaliwal, R., Kantores, C., Ivanovska, J., Gosal, K., McNamara, P. J., Letarte, M., & Jankov, R. P. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0131oc · Cited by 43
A Case of Takotsubo Cardiomyopathy During 5-Fluorouracil Treatment for Rectal Adenocarcinoma
Kobayashi, N., Hata, N., Yokoyama, S., Shinada, T., Shirakabe, A., & Mizuno, K. (2009) · Journal of Nippon Medical School · doi:10.1272/jnms.76.27 · Cited by 42
Acute Coronary Syndromes Complicating the First Infusion of Rituximab
Armitage, J. D., Montero, C., Benner, A., Armitage, J. O., & Bociek, G. R. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.035 · Cited by 41
Acute Limb Ischemia in Cancer Patients: Should We Surgically Intervene?
Tsang, J. S., Naughton, P. A., O’Donnell, J., Wang, T. T., Moneley, D. S., Kelly, C. J., & Leahy, A. L. (2011) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2011.06.002 · Cited by 40
Takotsubo Syndrome in a Patient Treated With Sunitinib for Renal Cancer
Numico, G., Sicuro, M., Silvestris, N., Mozzicafreddo, A., Trogu, A., Malossi, A., Cristofano, A., & Thiebat, B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4911 · Cited by 40
Ito, D., Shiraishi, J., Nakamura, T., Maruyama, N., Iwamura, Y., Hashimoto, S., Kimura, M., Matsui, A., Yokoi, H., Arihara, M., et al. (2012) · Heart and Vessels · doi:10.1007/s00380-011-0222-5 · Cited by 39
5 flourouracil-induced apical ballooning syndrome: a case report
Gianni, M., Dentali, F., & Lonn, E. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328329e431 · Cited by 38
Schrader, C., Keussen, C., Bewig, B., et al. (2005) · PubMed · Cited by 34
Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
Mayer, K. T., Gielen, G. H., Willinek, W. A., Muller, M. C., & Wolf, D. G. F. (2013) · Leukemia · doi:10.1038/leu.2013.320 · Cited by 31
Digital ischemic events related to gemcitabine: Report of two cases and a systematic review
Kuhar, C. G., Mesti, T., & Zakotnik, B. (2010) · Radiology and Oncology · doi:10.2478/v10019-010-0020-1 · Cited by 29
Xu, J., Millard, M., Ren, X., Cox, Ó. T., & Erdreich‐Epstein, A. (2010) · Blood · doi:10.1182/blood-2009-05-223776 · Cited by 28
Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
Tefferi, A. (2013) · Leukemia · doi:10.1038/leu.2013.112 · Cited by 27
A case of variant angina in a patient under chronic treatment with sorafenib
Porto, I., Leo, A., Miele, L., Pompili, M., Landolfi, R., & Crea, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.67 · Cited by 27
Schroll, S., Lange, T. J., Arzt, M. E., Sebah, D., Nowrotek, A., Lehmann, H., Wensel, R., Pfeifer, M. A., & Blumberg, F. C. (2013) · Acta Physiologica · doi:10.1111/apha.12085 · Cited by 23
Gemcitabine-Induced Acute Coronary Syndrome: A Case Report
Öztürk, B., Taçoy, G. A., Coşkun, U., Yaman, E., Sahin, G., Buyukberber, S., Yıldız, R., Ali Osman, K. A. Y. A., Topal, S., Özdemir, M., et al. (2008) · Medical Principles and Practice · doi:10.1159/000163051 · Cited by 20
Cardiac stunning as a manifestation of ATRA differentiation syndrome in acute promyelocytic leukemia
Santis, G. C. D., Madeira, M. I. A., de Oliveira, L. C. O., Falcão, R. P., & Rego, E. M. (2011) · Medical Oncology · doi:10.1007/s12032-010-9813-8 · Cited by 19
Dechant, C., Baur, M., Böck, R., Czejka, M. J., Podczeck-Schweighofer, A., Dittrich, C., & Christ, G. (2012) · Case Reports in Oncology · doi:10.1159/000339573 · Cited by 19
Breccia, M., Colafigli, G., Molica, M., & Alimena, G. (2015) · American Journal of Hematology · doi:10.1002/ajh.23976 · Cited by 16
Moyamoya in a Child Treated With Interferon for Recurrent Osteosarcoma
Buchbinder, D. K., Steinberg, G. K., Linetsky, M., & Casillas, J. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181e5e1db · Cited by 6
Ischaemic stroke in a patient on sunitinib: Figure 1
Lonergan, M., Kellehar, F., McDermott, R., et al. (2010) · BMJ Case Reports · doi:10.1136/bcr.01.2009.1420 · Cited by 6
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab674 · Cited by 645
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Metadata
- Authors
- Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K.
- Venue
- Circulation
- Published
- 2016-03-29
- Volume
- 133
- Issue
- 13
- Pages
- 1272-1289
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2328437427
- Cited by
- 329
- References
- 108
- FWCI
- 26.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.